Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.
Recently, we have developed the world’s first fully automated synthesis module, for the synthesis of Pt-195m cisplatin and other platinum compounds
A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.
In 2017, there was suddenly a worldwide shortage of iodine-125, used for brachytherapy for prostate cancer, because one of the large producers was temporarily shut down. McMaster & NRG joined forces for global supply.